Gert A Verpooten

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/12004849/publications.pdf

Version: 2024-02-01

34 papers	2,207 citations	279798 23 h-index	414414 32 g-index
35 all docs	35 docs citations	35 times ranked	2162 citing authors

#	Article	IF	Citations
1	Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapy. PLoS ONE, 2021, 16, e0252646.	2.5	1
2	Longitudinal Study of the Role of Epidermal Growth Factor on the Fractional Excretion of Magnesium in Children: Effect of Calcineurin Inhibitors. Nutrients, 2018, 10, 677.	4.1	9
3	Impaired vascular function contributes to exercise intolerance in chronic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 2064-2072.	0.7	50
4	Plasma levels of microRNA in chronic kidney disease: patterns in acute and chronic exercise. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 309, H2008-H2016.	3.2	44
5	Effect of Moderate Aerobic Exercise Training on Endothelial Function and Arterial Stiffness in CKD Stages 3-4: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2015, 66, 285-296.	1.9	80
6	Acute Exercise-Induced Response of Monocyte Subtypes in Chronic Heart and Renal Failure. Mediators of Inflammation, 2014, 2014, 1-11.	3.0	23
7	Magnesium loss in cyclosporine-treated patients is related to renal epidermal growth factor downregulation. Nephrology Dialysis Transplantation, 2014, 29, 1097-1102.	0.7	31
8	Complement factor H mutation associated with membranoproliferative glomerulonephritis with transformation to atypical haemolytic uraemic syndrome. CKJ: Clinical Kidney Journal, 2013, 6, 216-219.	2.9	14
9	The TRPM6/EGF Pathway Is Downregulated in a Rat Model of Cisplatin Nephrotoxicity. PLoS ONE, 2013, 8, e57016.	2.5	47
10	Expression of renal distal tubule transporters TRPM6 and NCC in a rat model of cyclosporine nephrotoxicity and effect of EGF treatment. American Journal of Physiology - Renal Physiology, 2011, 301, F486-F493.	2.7	36
11	Fibrous Intimal Thickening at Implantation Adversely Affects Long-Term Kidney Allograft Function. Transplantation, 2009, 87, 72-78.	1.0	25
12	Exposure of the elderly to potential nephrotoxic drug combinations in Belgium. Pharmacoepidemiology and Drug Safety, 2008, 17, 1014-1019.	1.9	18
13	Chronic Allograft Nephropathy: What Have We Learned From Protocol Biopsies?. Transplantation, 2008, 85, S38-S41.	1.0	34
14	Conversion from Cyclosporine to Sirolimus in Stable Renal Transplant Recipients. Transplantation, 2005, 80, 1578-1585.	1.0	54
15	Effect of immunosuppression on damage, leukocyte infiltration, and regeneration after severe warm ischemia/reperfusion renal injury. Kidney International, 2003, 64, 864-873.	5.2	49
16	Aminoglycosides and vancomycin. , 2003, , 151-170.		7
17	Oxidative modification of low-density lipoproteins and the outcome of renal allografts at 11/2 years. Kidney International, 2001, 59, 2346-2356.	5.2	60
18	TIMP-1 gene expression and PAI-1 antigen after unilateral ureteral obstruction in the adult male rat. Kidney International, 2000, 58, 1186-1201.	5.2	58

#	Article	IF	Citations
19	Identification and kinetics of leukocytes after severe ischaemia/reperfusion renal injury. Nephrology Dialysis Transplantation, 2000, 15, 1562-1574.	0.7	331
20	FIBROUS INTIMAL THICKENING AT IMPLANTATION AS A RISK FACTOR FOR THE OUTCOME OF CADAVERIC RENAL ALLOGRAFTS1. Transplantation, 2000, 69, 2388-2394.	1.0	64
21	The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation*. Clinical Pharmacology and Therapeutics, 1998, 64, 672-683.	4.7	383
22	A meta-analysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune diseases. Kidney International, 1998, 54, 536-545.	5.2	68
23	Inhibition of the matrix metalloproteinase system in a rat model of chronic cyclosporine nephropathy. Kidney International, 1998, 54, 804-818.	5.2	74
24	Aminoglycosides and vancomycin. , 1998, , 105-120.		2
25	Cholesterol feeding accentuates the cyclosporine-induced elevation of renal plasminogen activator inhibitor type 1. Kidney International, 1997, 51, 1818-1830.	5.2	22
26	Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clinical Pharmacology and Therapeutics, 1989, 45, 22-27.	4.7	207
27	Aminoglycoside Nephrotoxicity: Mechanism and Prevention. Advances in Experimental Medicine and Biology, 1989, 252, 233-245.	1.6	10
28	Acute Oligo-Anuria During Ovarian Hyperstimulation Syndrome. Acta Obstetricia Et Gynecologica Scandinavica, 1987, 66, 741-743.	2.8	5
29	Choice of drug and dosage regimen: Two important risk factors for aminoglycoside nephrotoxicity. American Journal of Medicine, 1986, 80, 115-118.	1.5	68
30	The Effect of Dosing Strategy on Kidney Cortical Accumulation of Aminoglycosides in Rats. American Journal of Kidney Diseases, 1986, 8, 297-303.	1.9	56
31	Renal Cortical Uptake Kinetics of Gentamicin in Rats With Impaired Renal Function. American Journal of Kidney Diseases, 1986, 8, 304-307.	1.9	9
32	Measurement of propericiazine in plasma by capillary gas chromatography and selected ion monitoring detection. Biological Mass Spectrometry, 1985, 12, 25-29.	0.5	3
33	Recovery of cortical phospholipidosis and necrosis after acute gentamicin loading in rats. Kidney International, 1984, 26, 838-847.	5.2	98
34	Early effects of gentamicin, tobramycin, and amikacin on the human kidney. Kidney International, 1984, 25, 643-652.	5.2	167